Written by the AllMyPeptides Research Team
Structural Differences
BPC-157 and TB-500 differ fundamentally in their molecular structure and origin:
- BPC-157: A 15-amino-acid synthetic peptide derived from a protective protein in human gastric juice. Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. MW: ~1419.5 g/mol.
- TB-500: A 43-amino-acid fragment of thymosin beta-4, a naturally occurring protein found in all mammalian cells. MW: ~4963.4 g/mol.
These structural differences directly influence their mechanisms of action and the types of research each peptide is suited for.
Mechanism of Action
The two peptides work through different cellular pathways:
- BPC-157: Research suggests interactions with the nitric oxide (NO) pathway, effects on VEGF expression, and modulation of growth factors. Studies have explored its effects on tendon fibroblasts and angiogenesis.
- TB-500: Research focuses on actin regulation and cell migration. TB-500 binds to actin monomers and affects cytoskeletal dynamics, which influences cell motility and tissue remodelling.
These different mechanisms mean researchers may choose one peptide over the other depending on their specific research focus.
Research Context Comparison
The choice between BPC-157 and TB-500 depends on your research area:
| Research Area | BPC-157 | TB-500 |
|---|---|---|
| Tendon/Ligament | Extensively studied | Studied |
| Cell Migration | Moderate | Primary focus |
| Angiogenesis | Primary focus | Moderate |
| GI Research | Studied | Limited |
| Muscle Research | Studied | Studied |
Frequently Asked Questions
Can BPC-157 and TB-500 be used together in research?+
Which peptide is better for angiogenesis research?+
Which peptide is larger?+
Are both peptides legal in the UK?+
Related Guides
Products discussed in this guide are for research and laboratory use only. AllMyPeptides does not condone or support misuse of any research materials. Not for human or animal consumption.
